AbbVie Inc (ABBV)vsPhibro Animal Health Corporation (PAHC)
ABBV
AbbVie Inc
$263.65
+0.04%
HEALTHCARE · Cap: $447.53B
PAHC
Phibro Animal Health Corporation
$36.95
+1.59%
HEALTHCARE · Cap: $1.34B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4088% more annual revenue ($62.82B vs $1.50B). PAHC leads profitability with a 6.3% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.42. PAHC earns a higher WallStSmart Score of 65/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
PAHC
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$263.65
$116.39 premium
Margin of Safety
-11.4%
Fair Value
$46.24
Current Price
$36.95
$9.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Expensive relative to growth rate
Smaller company, higher risk/reward
6.3% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : PAHC
The strongest argument for PAHC centers on Return on Equity, P/E Ratio. Revenue growth of 10.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : PAHC
The primary concerns for PAHC are PEG Ratio, Market Cap, Profit Margin. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
PAHC carries more volatility with a beta of 0.46 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PAHC scores higher overall (65/100 vs 63/100) and 10.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Phibro Animal Health Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?